Holm Nielsen, Signe http://orcid.org/0000-0002-4612-1014
Mortensen, Joachim Høg
Willumsen, Nicholas
Rasmussen, Daniel Guldager Kring http://orcid.org/0000-0003-1642-7482
Mogensen, Ditte J.
Di Sabatino, Antonio
Mazza, Giuseppe
Jørgensen, Lars Nannestad
Giuffrida, Paolo
Pinzani, Massimo
Klinge, Lone
Kjeldsen, Jens
Leeming, Diana Julie
Karsdal, Morten Asser
Genovese, Federica
Funding for this research was provided by:
Innovation Foundation The Danish Research Fund
Article History
Received: 9 September 2019
Accepted: 12 March 2020
First Online: 3 April 2020
Competing interests
: S.H.N., J.H.M., N.W., D.J.L., M.A.K. and F.G. are full-time employees at Nordic Bioscience. Nordic, Bioscience is a privately-owned, small–medium size enterprise partly focused on the development of biomarkers. None of the authors received fees, bonuses or other benefits for the work described in the manuscript. D.J.L., M.A.K. and F.G. holds stocks in Nordic Bioscience. The patent for the ELISA used to assess C6Mα3 levels is owned by Nordic Bioscience. The funder provided support in the form of salaries for authors D.G.K.R., M.A.K. and F.G., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors report no competing financial interests relevant to this manuscript.